{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:29:53Z","timestamp":1782937793646,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:00:00Z","timestamp":1594080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:00:00Z","timestamp":1594080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["17K08703"],"award-info":[{"award-number":["17K08703"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We previously demonstrated that ovarian high grade serous carcinomas (OHGSeCa) and ovarian clear cell carcinomas (OCCCa) with an HNF-1\u03b2+\/p53+\/ARID1A+ immunophenotype were associated with the worst unfavorable prognosis. To clarify the molecular mechanisms underlying this finding, we focused on alterations in the p53 signaling pathway in these tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Changes in cell phenotype and function following knockdown of wild-type p53 (p53-KD) were assessed using OCCCa cells expressing endogenous HNF-1\u03b2 and ARID1A. The prognostic significance of molecules that were deregulated following p53-KD was also examined using 129 OCCCa\/OHGSeCa cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      p53-KD cells had increased expression of Snail, phospho-Akt (pAkt), and pGSK3\u03b2, and decreased E-cadherin expression, leading to epithelial-mesenchymal transition (EMT)\/cancer stem cell (CSC) features. The cells also exhibited acceleration of cell motility and inhibition of cell proliferation and apoptosis. Next generation sequencing revealed that fibronectin (FN) expression was significantly increased in the p53 KD-cells, in line with our observation that wild-type p53 (but not mutant p53) repressed\n                      <jats:italic>FN1<\/jats:italic>\n                      promoter activity. In addition, treatment of OCCCa cells with FN significantly increased cell migration capacity and decreased cell proliferation rate, independent of induction of EMT features. In clinical samples, FN\/p53 scores were significantly higher in OCCCa\/OHGSeCa with the HNF-1\u03b2+\/p53+\/ARID1A+ immunophenotype when compared to others. Moreover, high FN\/high p53 expression was associated with the worst overall survival and progression-free survival in OCCCa\/OHGSeCa patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest that upregulation of FN following loss of p53 function may impact the biological behavior of OCCCa\/OHGSeCa, particularly in tumors with an HNF-1\u03b2+\/p53+\/ARID1A+ immunophenotype, through alterations in cell mobility and cell proliferation. The accompanying induction of EMT\/CSC properties and inhibition of apoptosis due to p53 abnormalities also contribute to the establishment and maintenance of tumor phenotypic characteristics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12964-020-00580-3","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T09:03:59Z","timestamp":1594112639000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Upregulation of fibronectin following loss of p53 function is a poor prognostic factor in ovarian carcinoma with a unique immunophenotype"],"prefix":"10.1186","volume":"18","author":[{"given":"Ako","family":"Yokoi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihide","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Oguri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Tochimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Saegusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,7]]},"reference":[{"key":"580_CR1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","volume":"57","author":"A Jemal","year":"2007","unstructured":"Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43\u201363.","journal-title":"CA Cancer J Clin"},{"key":"580_CR2","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/sj.bjc.6601537","volume":"90","author":"Y Wang","year":"2004","unstructured":"Wang Y, Helland A, Holm R, Skomedal H, Abeler VM, Danielsen HE, Trope CG, Borresen-Dale A-L, Kristensen GB. TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival. Br J Cancer. 2004;90:678\u201385.","journal-title":"Br J Cancer"},{"key":"580_CR3","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ajog.2011.03.008","volume":"204","author":"R Salani","year":"2001","unstructured":"Salani R, Backes FJ, Fung MF, Holschneider CH, Parker LP, Bristow RE, Goff BA. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol. 2001;204:466\u201378.","journal-title":"Am J Obstet Gynecol"},{"key":"580_CR4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1126\/science.1905840","volume":"253","author":"M Hollstein","year":"1991","unstructured":"Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49\u201353.","journal-title":"Science."},{"key":"580_CR5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrc3711","volume":"14","author":"KT Bieging","year":"2014","unstructured":"Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumor suppression. Nat Rev Cancer. 2014;14:359\u201370.","journal-title":"Nat Rev Cancer"},{"key":"580_CR6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2641","volume":"15","author":"PA Muller","year":"2013","unstructured":"Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013;15:2\u20138.","journal-title":"Nat Cell Biol"},{"key":"580_CR7","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc2693","volume":"9","author":"R Brosh","year":"2009","unstructured":"Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 2009;9:701\u201313.","journal-title":"Nat Rev Cancer"},{"key":"580_CR8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/1471-2407-10-237","volume":"10","author":"MQ Bernardini","year":"2010","unstructured":"Bernardini MQ, Baba T, Lee PS, Bamett JC, Sfakianos GP, Secord AA, Murphy SK, Iversen E, Marks JR, Berchuck A. Expression signature of TP53 mutations in serous ovarian cancers. BMC Cancer. 2010;10:237.","journal-title":"BMC Cancer"},{"key":"580_CR9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/path.1000","volume":"195","author":"JM Piek","year":"2001","unstructured":"Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijien RH. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195:451\u20136.","journal-title":"J Pathol"},{"key":"580_CR10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.2091","volume":"211","author":"Y Lee","year":"2007","unstructured":"Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, Cramer DW, McKeon FD, Crum CP. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26\u201335.","journal-title":"J Pathol"},{"key":"580_CR11","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1200\/JCO.2008.16.4814","volume":"26","author":"JW Carlson","year":"2008","unstructured":"Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, Muto MG, Kindelberger D, Crum CP. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol. 2008;26:4160\u20135.","journal-title":"J Clin Oncol"},{"key":"580_CR12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.humpath.2018.10.036","volume":"85","author":"A Yokoi","year":"2019","unstructured":"Yokoi A, Matsumoto T, Watanabe G, Tochimoto M, Saegusa M. Immunophenotypic profile as a predictor of prognosis in advanced ovarian carcinoma. Hum Pathol. 2019;85:210\u201320.","journal-title":"Hum Pathol"},{"key":"580_CR13","doi-asserted-by":"crossref","first-page":"63646","DOI":"10.18632\/oncotarget.18882","volume":"8","author":"M Akiya","year":"2017","unstructured":"Akiya M, Yamazaki M, Matsumoto T, Kawashima Y, Oguri Y, Kajita S, Kijima D, Chiba R, Yokoi A, Takahashi H, Kodera Y, Saegusa M. Identification of LEFTY as a molecular marker for ovarian clear cell carcinoma. Oncotarget. 2017;8:63646\u201364.","journal-title":"Oncotarget."},{"key":"580_CR14","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0002-9440(10)63732-7","volume":"164","author":"M Seagusa","year":"2004","unstructured":"Seagusa M, Hashimura M, Kuwata T, Hamano M, Okayasu I. \u03b2-Catenin simultaneously indices activation of the p53-p21WAF1 pathway and overexpression of cyclin D1 during squamous differentiation of endometrial carcinoma cells. Am J Pathol. 2004;164:1739\u201349.","journal-title":"Am J Pathol"},{"key":"580_CR15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/path.2198","volume":"213","author":"M Seagusa","year":"2007","unstructured":"Seagusa M, Hashimura M, Kuwata T, Hamano M, Okayasu I. Crosstalk between NF-\u03baB\/p65 and \u03b2-catenin\/TCF4\/p300 signalling pathways through alterations in GSK-3\u03b2 expression during trans-differentiation of endometrial carcinoma cells. J Pathol. 2007;213:35\u201345.","journal-title":"J Pathol"},{"key":"580_CR16","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/labinvest.2015.73","volume":"95","author":"E Suzuki","year":"2015","unstructured":"Suzuki E, Kajita S, Takahashi H, Matsumoto T, Tsuruta T, Saegusa M. Transcriptional upregulation of HNF-1\u03b2 by NF-\u03baB in ovarian clear cell carcinoma modulates susceptibility to apoptosis through alteration in bcl-2 expression. Lab Investig. 2015;95:962\u201372.","journal-title":"Lab Investig"},{"key":"580_CR17","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/mc.22816","volume":"57","author":"T Matsumoto","year":"2018","unstructured":"Matsumoto T, Yokoi A, Hashimura M, Oguri Y, Akiya M, Saegusa M. TGF-\u03b2-mediated LEFTY\/Akt\/GSK-3\u03b2\/snail axis modulates epithelial-mesenchymal transition and cancer stem cell properties in ovarian clear cell carcinomas. Mol Carcinog. 2018;57:957\u201367.","journal-title":"Mol Carcinog"},{"key":"580_CR18","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J","volume":"73","author":"JF Kerr","year":"1994","unstructured":"Kerr JF, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer. 1994;73:2013\u201326.","journal-title":"Cancer."},{"key":"580_CR19","doi-asserted-by":"crossref","first-page":"R106","DOI":"10.1186\/gb-2010-11-10-r106","volume":"11","author":"S Aders","year":"2010","unstructured":"Aders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11:R106.","journal-title":"Genome Biol"},{"key":"580_CR20","unstructured":"Longacre TA, Wells M, Bell DA, Malpica A, Prat J, Ronnet BM. Tumours of the tumours of the ovary. In: Kurman RJ, Carcangiu ML, HerringtonCS, Young RH, editors. WHO Classification of Tumours of Female Reproductive Organs. Lyon: IARC; 2014. p. 11-86."},{"key":"580_CR21","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/modpathol.2011.85","volume":"24","author":"A Yemelyanova","year":"2011","unstructured":"Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih le M, Kurman RJ. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinomas: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol. 2011;24:1248\u201353.","journal-title":"Mod Pathol"},{"key":"580_CR22","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","volume":"133","author":"SA Mani","year":"2008","unstructured":"Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704\u201315.","journal-title":"Cell."},{"key":"580_CR23","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/onc.2013.118","volume":"33","author":"J Park","year":"2014","unstructured":"Park J, Schwarzbauer JE. Mammary epithelial cell interactions with fibronectin stimulate epithelial-mesenchymal transition. Oncogene. 2014;33:1649\u201357.","journal-title":"Oncogene."},{"key":"580_CR24","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.3892\/ol.2017.5896","volume":"13","author":"C-L Li","year":"2017","unstructured":"Li C-L, Yang D, Cao X, Wang F, Hong D-Y, Wang J, Shen X-C, Chen Y. Fibronectin induces epithelial-mesenchymal transition in human breast cancer MCF-7 cells via activation of calpain. Oncol Lett. 2017;13:3889\u201395.","journal-title":"Oncol Lett"},{"key":"580_CR25","doi-asserted-by":"crossref","first-page":"e0118029","DOI":"10.1371\/journal.pone.0118029","volume":"10","author":"D Jiang","year":"2015","unstructured":"Jiang D, Dumur CI, Massey HD, Ramakrishan V, Subler MA, Windle JJ. Comparison of effect of p53 null and gain-of-function mutations on salivary tumors in MMTV-Hras transgenic mice. PLoS One. 2015;10:e0118029.","journal-title":"PLoS One"},{"key":"580_CR26","doi-asserted-by":"crossref","first-page":"10280","DOI":"10.1158\/0008-5472.CAN-05-2193","volume":"65","author":"EL Jackson","year":"2005","unstructured":"Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M, Jacks T. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 2005;65:10280\u20138.","journal-title":"Cancer Res"},{"key":"580_CR27","doi-asserted-by":"crossref","first-page":"8166","DOI":"10.1158\/0008-5472.CAN-05-1650","volume":"65","author":"SW Wijnhoven","year":"2005","unstructured":"Wijnhoven SW, Zwart E, Speksnijder EN, Beems RB, Olive KP, Tuveson DA, Jonkers J, Schaap MM, van den Berg J, Jacks T, van Steeg H, de Vries A. Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res. 2005;65:8166\u201373.","journal-title":"Cancer Res"},{"key":"580_CR28","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1073\/pnas.97.8.4174","volume":"97","author":"G Liu","year":"2000","unstructured":"Liu G, McDonnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, El-Naggar AK, Lozano G. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci USA. 2000;97:4174\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"580_CR29","first-page":"249","volume":"5","author":"MP Kim","year":"2015","unstructured":"Kim MP, Zhang Y, Lozano G. mutant p53: multiple mechanisms define biologic activity in cancer. Front Oncol. 2015;5:249.","journal-title":"Front Oncol"},{"key":"580_CR30","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/PGP.0b013e318273fd07","volume":"32","author":"D DeLair","year":"2013","unstructured":"DeLair D, Han G, Irving JA, Leung S, Ewanowich CA, Longacre TA, Gilks CB, Soslow RA. HNF-1\u03b2 in ovarian carcinomas with serous and clear cell change. Int J Gynecol Pathol. 2013;32:541\u20136.","journal-title":"Int J Gynecol Pathol"},{"key":"580_CR31","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/ncb1173","volume":"6","author":"BP Zhou","year":"2004","unstructured":"Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, Hung MC. Dual regulation of snail by GSK-3\u03b2-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol. 2004;6:931\u201340.","journal-title":"Nat Cell Biol"},{"key":"580_CR32","first-page":"2739","volume":"41","author":"JX Lin","year":"2019","unstructured":"Lin JX, Xie XS, Weng XF, Qiu SL, Xie JW, Wang JB, Lu J, Chen QY, Cao LL, Lin M, Tu RH, Li P, Huang CM, Zheng CH. Overexpression of IC53d promotes the proliferation of gastric cancer cells by activating the AKT\/GSK-3\u03b2\/cyclin D1 signaling pathway. Oncol Rep. 2019;41:2739\u201352.","journal-title":"Oncol Rep"},{"key":"580_CR33","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1529\/biophysj.105.077693","volume":"91","author":"KB Wee","year":"2006","unstructured":"Wee KB, Aguda BD. Akt versus p53 in a network of oncogenes and tumor suppressor genes regulating cell survival and death. Biophys J. 2006;91:857\u201365.","journal-title":"Biophys J"},{"key":"580_CR34","doi-asserted-by":"crossref","first-page":"e4407","DOI":"10.1371\/journal.pone.0004407","volume":"4","author":"KB Wee","year":"2009","unstructured":"Wee KB, Surana U, Aguda BD. Oscillations of the p53-Akt network: implications on cell survival and death. PLoS One. 2009;4:e4407.","journal-title":"PLoS One"},{"key":"580_CR35","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/sj.onc.1205181","volume":"21","author":"TM Gottlieb","year":"2002","unstructured":"Gottlieb TM, Leal JFM, Seger R, Taya Y, Oren M. Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene. 2002;21:1299\u2013303.","journal-title":"Oncogene."},{"key":"580_CR36","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1038\/onc.2012.334","volume":"32","author":"P Dong","year":"2013","unstructured":"Dong P, Karaayvaz M, Jia N, Kaneuchi M, Hamada J, Watari H, Sudo S, Ju J, Sakuragi N. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene. 2013;32:3286\u201395.","journal-title":"Oncogene."},{"key":"580_CR37","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.febslet.2010.04.006","volume":"584","author":"S-O Lim","year":"2010","unstructured":"Lim S-O, Kim H, Jung G. p53 inhibits tumor cell invasion via the degradation of snail protein in hepatocellular carcinoma. FEBS Lett. 2010;584:2231\u20136.","journal-title":"FEBS Lett"},{"key":"580_CR38","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1128\/MCB.01536-07","volume":"28","author":"SR Payne","year":"2008","unstructured":"Payne SR, Zhang S, Tsuchiya K, Moser R, Gurley KE, Longton G, DeBoer J, Kemp CJ. p27kip1 deficiency impairs G2\/M arrest in response to DNA damage leading to an increase in genetic instability. Mol Cell Biol. 2008;28:258\u201368.","journal-title":"Mol Cell Biol"},{"key":"580_CR39","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/344503a0","volume":"344","author":"P Nurse","year":"1990","unstructured":"Nurse P. Universal control mechanism regulating onset of M-phase. Nature. 1990;344:503\u20138.","journal-title":"Nature."},{"key":"580_CR40","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1534-5807(04)00131-5","volume":"6","author":"K Nakayama","year":"2004","unstructured":"Nakayama K, Nagahama H, Minamishima A, Miyake S, Ishida N, Hatakeyama S, Kitagawa M, Iemura S, Natsume T, Nakayama KI. Skp2-mediated degradation of p27 regulates progression into mitosis. Dev Cell. 2004;6:661\u201372.","journal-title":"Dev Cell"},{"key":"580_CR41","first-page":"6304","volume":"51","author":"MB Kastan","year":"1991","unstructured":"Kastan MB, Onvekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51:6304\u201311.","journal-title":"Cancer Res"},{"key":"580_CR42","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/nm0196-72","volume":"2","author":"AF Wahl","year":"1996","unstructured":"Wahl AF, Donaldson KL, Faircnild C, Lee FYF, Foster SA, Demers GW, Galloway DA. Loss of normal p53 function confers sensitization to Taxol by increasing G2\/M arrest and apoptosis. Nat Med. 1996;2:72\u20139.","journal-title":"Nat Med"},{"key":"580_CR43","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/(SICI)1097-0215(19960717)67:2<275::AID-IJC20>3.0.CO;2-9","volume":"67","author":"A Giese","year":"1996","unstructured":"Giese A, Loo MA, Tran N, Haskett D, Coons SW, Berens ME. Dichotomy of astrocytoma migration and proliferation. Int J Cancer. 1996;67:275\u201382.","journal-title":"Int J Cancer"},{"key":"580_CR44","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1200\/JCO.2003.05.063","volume":"21","author":"A Giese","year":"2003","unstructured":"Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant glioma and implications for treatment. J Clin Oncol. 2003;21:1624\u201336.","journal-title":"J Clin Oncol"},{"key":"580_CR45","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/bjc.1994.280","volume":"70","author":"A Merzak","year":"1994","unstructured":"Merzak A, McCrea S, Koocheckpour S, Pilkington GJ. Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor beta 1. Br J Cancer. 1994;70:199\u2013203.","journal-title":"Br J Cancer"},{"key":"580_CR46","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1073\/pnas.97.2.529","volume":"97","author":"J Pawloaski","year":"2000","unstructured":"Pawloaski J, Kraft AS. Bax-induced apoptotic cell death. Proc Natl Acad Sci U S A. 2000;97:529\u201331.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"580_CR47","first-page":"629","volume":"7","author":"V Iotsova","year":"1996","unstructured":"Iotsova V, Stehelin D. Down-regulation of fibronectin gene expression by the p53 tumor suppressor protein. Cell Growth Differ. 1996;7:629\u201334.","journal-title":"Cell Growth Differ"},{"key":"580_CR48","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.3892\/or.2017.5860","volume":"38","author":"D You","year":"2017","unstructured":"You D, Jung SP, Jeong Y, Bae SY, Kim S. Wild-type p53 controls the level of fibronectin expression in breast cancer cells. Oncol Rep. 2017;38:2551\u20137.","journal-title":"Oncol Rep"},{"key":"580_CR49","doi-asserted-by":"crossref","first-page":"674","DOI":"10.7150\/jca.16901","volume":"8","author":"JP Wang","year":"2017","unstructured":"Wang JP, Hielscher A. Fibronectin: how its aberrant expression in tumors may improve therapeutic targeting. J Cancer. 2017;8:674\u201382.","journal-title":"J Cancer"},{"key":"580_CR50","doi-asserted-by":"crossref","first-page":"615","DOI":"10.5483\/BMBRep.2017.50.12.096","volume":"50","author":"D You","year":"2017","unstructured":"You D, Jung SP, Jeong Y, Bae SY, Lee JE, Kim S. Fibronectin expression is upregulated by PI-3K\/Akt activation in tamoxifen-resistant breast cancer cells. BMB Rep. 2017;50:615\u201320.","journal-title":"BMB Rep"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-020-00580-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-020-00580-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-020-00580-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T19:20:36Z","timestamp":1625599236000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-020-00580-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["580"],"URL":"https:\/\/doi.org\/10.1186\/s12964-020-00580-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.22626\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.22626\/v1","asserted-by":"object"}]},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,7]]},"assertion":[{"value":"29 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approval for this study was given by the Ethics Committee of the Kitasato University School of Medicine (B16\u201310).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The declare that they have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}